MCID: SLP001
MIFTS: 56

Sleeping Sickness

Categories: Eye diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

MalaCards integrated aliases for Sleeping Sickness:

Name: Sleeping Sickness 12 20 53 58 3 15
African Trypanosomiasis 12 74 58 3 15 71 32
Trypanosomiasis, Human East-African 20
Human African Trypanosomiasis 17
African Sleeping Sickness 12
Trypanosomiasis, African 44
Trypanosomiasis African 54

Characteristics:

Orphanet epidemiological data:

58
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Sleeping Sickness

NINDS : 53 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to trypanosomiasis and leishmaniasis. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are African trypanosomiasis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Nifurtimox and Ornithine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and heart, and related phenotypes are narcolepsy and excessive daytime somnolence

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

CDC : 3 African Trypanosomiasis, also known as "sleeping sickness", is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Wikipedia : 74 African trypanosomiasis, also known as African sleeping sickness or simply sleeping sickness, is an... more...

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 31.7 TF ODC1 IL6 IL10 HPR HP
2 leishmaniasis 31.2 SRM NOS2 MDH2 IL6 IL10
3 chagas disease 31.0 SRM ODC1 NOS2 IL6 IL10 GSR
4 malaria 30.9 SRM NOS2 IL6 IL10 HP GSR
5 disease by infectious agent 30.8 PRODH IL6 IL10 HP H2AC18
6 acute cystitis 30.7 IL6 IL10 H2AC18
7 dysentery 30.5 TF IL6 IL10 HP H2AC18
8 filariasis 30.5 NOS2 IL6 IL10
9 orchitis 30.5 IL6 IL10 H2AC18
10 exanthem 30.5 IL6 IL10 H2AC18
11 parasitic helminthiasis infectious disease 30.5 IL6 IL10 H2AC18
12 deficiency anemia 30.4 TF IL6 HP H2AC18 GSR GAPDH
13 placenta disease 30.3 PRODH IL6 H2AC18
14 central nervous system disease 30.2 PRODH NOS2 IL6 H2AC18
15 parasitic protozoa infectious disease 30.2 PRODH IL6 IL10 HP H2AC18 APOL1
16 nervous system disease 30.1 PRODH NOS2 IL6 IL10 H2AC18 GAPDH
17 eye disease 30.1 PRODH IL6 IL10 H2AC18 GAPDH APOA1
18 von economo's disease 11.3
19 trypanosomiasis, human west-african 11.2
20 eastern equine encephalitis 11.1
21 acute gonococcal cervicitis 10.5 IL6 IL10
22 retina lymphoma 10.5 IL10 CXCL13
23 spotted fever rickettsiosis 10.5 NOS2 IL10
24 eye lymphoma 10.5 IL6 IL10 CXCL13
25 kala-azar 1 10.5
26 vaginal discharge 10.5 IL6 IL10 HP
27 neurosyphilis 10.5 IL10 CXCL13
28 bronchopneumonia 10.5 IL6 IL10 HP
29 endometrial disease 10.5 IL6 IL10 HP
30 trachoma 10.5 IL6 IL10 HP
31 autoimmune disease of blood 10.5 IL6 IL10 HP
32 syndromic x-linked intellectual disability snyder type 10.5 SRM ODC1 AMD1
33 acute transverse myelitis 10.4 IL6 IL10 APOA1
34 transverse myelitis 10.4 IL6 IL10 APOA1
35 rheumatic fever 10.4 IL6 IL10 HP
36 psoriasis 13 10.4 IL6 IL10 GAPDH
37 endometritis 10.4 IL6 HP CXCL13
38 vaginal disease 10.4 IL6 IL10 H2AC18
39 herpangina 10.4 IL6 IL10 H2AC18
40 cataract 4, multiple types 10.4 IL6 IL10 GAPDH
41 splenic disease 10.4 IL6 IL10 H2AC18
42 listeriosis 10.4 IL6 IL10 H2AC18
43 coccidiosis 10.4 IL6 IL10 H2AC18
44 anus disease 10.4 IL6 IL10 H2AC18
45 coronavirus infectious disease 10.4 IL6 IL10 H2AC18
46 autoimmune disease of cardiovascular system 10.4 IL6 IL10 H2AC18
47 bacterial sepsis 10.4 NOS2 IL6 IL10
48 rectal disease 10.4 IL6 IL10 H2AC18
49 anhaptoglobinemia 10.4 HPR HP
50 central nervous system lymphoma 10.4 IL6 IL10 CXCL13

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

Human phenotypes related to Sleeping Sickness:

58 31 (show top 50) (show all 88)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 narcolepsy 58 31 hallmark (90%) Very frequent (99-80%) HP:0030050
2 excessive daytime somnolence 58 31 hallmark (90%) Very frequent (99-80%) HP:0001262
3 sleep-wake cycle disturbance 58 31 hallmark (90%) Very frequent (99-80%) HP:0006979
4 periodic fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0032323
5 muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0001324
6 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
7 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
8 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
9 insomnia 58 31 frequent (33%) Frequent (79-30%) HP:0100785
10 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
11 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
12 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
13 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
14 brain imaging abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0410263
15 abnormality of the cerebral white matter 58 31 frequent (33%) Frequent (79-30%) HP:0002500
16 hepatosplenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001433
17 apathy 58 31 frequent (33%) Frequent (79-30%) HP:0000741
18 difficulty walking 58 31 frequent (33%) Frequent (79-30%) HP:0002355
19 abnormal rapid eye movement sleep 58 31 frequent (33%) Frequent (79-30%) HP:0002494
20 abnormal ekg 58 31 frequent (33%) Frequent (79-30%) HP:0003115
21 abnormal basal ganglia mri signal intensity 58 31 frequent (33%) Frequent (79-30%) HP:0012751
22 rigors 58 31 frequent (33%) Frequent (79-30%) HP:0025145
23 neurological speech impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002167
24 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
25 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
26 dyskinesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100660
27 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
28 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
29 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
30 anxiety 58 31 occasional (7.5%) Occasional (29-5%) HP:0000739
31 alopecia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001596
32 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
33 jaundice 58 31 occasional (7.5%) Occasional (29-5%) HP:0000952
34 third degree atrioventricular block 58 31 occasional (7.5%) Occasional (29-5%) HP:0001709
35 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
36 ventriculomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002119
37 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
38 fasciculations 58 31 occasional (7.5%) Occasional (29-5%) HP:0002380
39 conjunctivitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000509
40 abnormality of the menstrual cycle 58 31 occasional (7.5%) Occasional (29-5%) HP:0000140
41 keratitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000491
42 gynecomastia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000771
43 infertility 58 31 occasional (7.5%) Occasional (29-5%) HP:0000789
44 impaired proprioception 58 31 occasional (7.5%) Occasional (29-5%) HP:0010831
45 impotence 58 31 occasional (7.5%) Occasional (29-5%) HP:0000802
46 choreoathetosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001266
47 hemiparesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001269
48 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
49 aggressive behavior 58 31 occasional (7.5%) Occasional (29-5%) HP:0000718
50 paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0003470

GenomeRNAi Phenotypes related to Sleeping Sickness according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.75 NOS2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.75 H2AC18 NOS2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.75 NOS2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-136 9.75 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.75 H2AC18 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.75 H2AC18
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 9.75 H2AC18
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 9.75 ODC1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.75 NOS2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-192 9.75 PRODH
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.75 ODC1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 9.75 PRODH
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.75 PRODH
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.75 H2AC18
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 9.75 PRODH
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.75 H2AC18
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 9.75 H2AC18
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-47 9.75 NOS2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-5 9.75 PRODH
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 9.75 NOS2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.75 PRODH
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.75 NOS2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.75 PRODH
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-99 9.75 NOS2 ODC1

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifurtimox Approved, Investigational Phase 3 23256-30-6
2
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
3 Melarsoprol Investigational Phase 3 494-79-1
4 polysaccharide-K Phase 2, Phase 3
5 Anti-Infective Agents Phase 3
6 Antiparasitic Agents Phase 3
7 Antiprotozoal Agents Phase 3
8
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
9
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
10
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
11
Pafuramidine Investigational Phase 2 186953-56-0
12
Maleic acid Experimental Phase 2 110-16-7 444266
13 Antifungal Agents Phase 2
14 Immunologic Factors
15 Immunoglobulin G
16 Immunoglobulin M
17 Immunoglobulins, Intravenous
18 Immunoglobulins
19 Antibodies

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Completed NCT02169557 Phase 2, Phase 3 Fexinidazole
3 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Completed NCT02184689 Phase 2, Phase 3 fexinidazole
4 Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
5 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
6 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring Recruiting NCT04099628 Phase 2, Phase 3
7 Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial Recruiting NCT03974178 Phase 2, Phase 3 Fexinidazole
8 Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study Active, not recruiting NCT03087955 Phase 2, Phase 3 Acoziborole (SCYX-7158)
9 An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Active, not recruiting NCT03025789 Phase 3 Fexinidazole
10 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
11 Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
12 Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
13 Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
14 Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers Completed NCT00982904 Phase 1 Fexinidazole/Placebo
15 A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition Completed NCT02571062 Phase 1 Fexinidazole
16 Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers Completed NCT01533961 Phase 1 SCYX-7158;Placebo
17 An Open Label, Single-dose, Single Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-Acoziborole Recruiting NCT04270981 Phase 1 [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
18 Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers. Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
19 Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria Unknown status NCT03394976
20 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
21 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure Active, not recruiting NCT03112655
22 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Active, not recruiting NCT03356665

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Eflornithine
Eflornithine Hydrochloride

Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

40
Brain, Eye, Heart, Kidney, T Cells, Bone Marrow, Skin

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 4420)
# Title Authors PMID Year
1
Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. 61 54
20220141 2010
2
Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. 54 61
19748525 2010
3
Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. 54 61
17643344 2007
4
Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. 54 61
17610127 2007
5
Synthesis and biological evaluation of phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase. 61 54
17615587 2007
6
A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane. 61 54
17407445 2007
7
Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents. 54 61
17504214 2007
8
In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei. 54 61
16896212 2006
9
The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness. 61 54
15217727 2004
10
The detection of bovine lactoferrin binding protein on Trypanosoma brucei. 61 54
15240935 2004
11
Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. 61 54
12805119 2003
12
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 54 61
12653650 2003
13
Transferrin coupled azanthraquinone enhances the killing effect on trypanosomes. The role of lysosomal mannosidase. 61 54
12514955 2002
14
Identification and functional characterization of thioredoxin from Trypanosoma brucei brucei. 61 54
10713060 2000
15
The transferrin receptor of Trypanosoma brucei. 54 61
11227758 2000
16
Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. 54 61
9174360 1997
17
Synthesis and structure-activity relationships of analogs of 2'-deoxy-2'-(3-methoxybenzamido)adenosine, a selective inhibitor of trypanosomal glycosomal glyceraldehyde-3-phosphate dehydrogenase. 61 54
7562915 1995
18
Polyamines as targets for therapeutic intervention. 54 61
7598507 1995
19
Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. 61 54
7932587 1994
20
Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. 54 61
8347171 1993
21
Modulation of trypanosome establishment in Glossina palpalis palpalis by its microbiome in the Campo sleeping sickness focus, Cameroon. 61
33571685 2021
22
Accelerating elimination of sleeping sickness from the Guinean littoral through enhanced screening in the post-Ebola context: A retrospective analysis. 61
33591980 2021
23
APEX2 Proximity Proteomics Resolves Flagellum Subdomains and Identifies Flagellum Tip-Specific Proteins in Trypanosoma brucei. 61
33568455 2021
24
Tryp-ing up metabolism: role of metabolic adaptations in kinetoplastid disease pathogenesis. 61
33526564 2021
25
The In Silico Identification of Potential Members of the Ded1/DDX3 Subfamily of DEAD-Box RNA Helicases from the Protozoan Parasite Leishmania infantum and Their Analyses in Yeast. 61
33535521 2021
26
Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice. 61
33594070 2021
27
Tsetse salivary glycoproteins are modified with paucimannosidic N-glycans, are recognised by C-type lectins and bind to trypanosomes. 61
33529215 2021
28
In-vitro Anti-trypanosomal and Cytotoxicity Evaluation of 3-methyl-3-4-dihydoquinazolin-2(1H)-one Derivatives. 61
33535253 2021
29
Update on relevant trypanosome peptidases: Validated targets and future challenges. 61
33271348 2021
30
Potential impacts of climate change on geographical distribution of three primary vectors of African Trypanosomiasis in Tanzania Maasai Steppe; G. m. morsitans, G. pallidipes and G. swynnertoni. 61
33571190 2021
31
Physiological and proteomic profiles of Trypanosoma brucei rhodesiense parasite isolated from suramin responsive and non-responsive HAT patients in Busoga, Uganda. 61
33588295 2021
32
New Pd-Fe ferrocenyl antiparasitic compounds with bioactive 8-hydroxyquinoline ligands: a comparative study with their Pt-Fe analogues. 61
33449983 2021
33
The ultimate fate determinants of drug induced cell-death mechanisms in Trypanosomatids. 61
33601284 2021
34
Effect of zebra skin-derived compounds on field catches of the human African trypanosomiasis vector Glossina fuscipes fuscipes. 61
33160957 2021
35
An atlas of tsetse and animal African trypanosomiasis in Zimbabwe. 61
33446276 2021
36
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis. 61
33497373 2021
37
Isolation, Structure Determination, and Total Synthesis of Hoshinoamide C, an Antiparasitic Lipopeptide from the Marine Cyanobacterium Caldora penicillata. 61
33369420 2021
38
The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines. 61
33070078 2021
39
Gene co-expression network analysis of Trypanosoma brucei in tsetse fly vector. 61
33482903 2021
40
Basic Biology of Trypanosoma brucei with reference to the development of chemotherapies. 61
33463458 2021
41
Optimizing the feeding frequency to maximize the production of sterile males in tsetse mass-rearing colonies. 61
33444421 2021
42
The function of apolipoproteins L (APOLs): relevance for kidney disease, neurotransmission disorders, cancer and viral infection. 61
32530132 2021
43
Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo. 61
33513134 2021
44
Genetic Diversity of African Trypanosomes in Tsetse Flies and Cattle From the Kafue Ecosystem. 61
33585616 2021
45
Reliable, scalable functional genetics in bloodstream-form Trypanosoma congolense in vitro and in vivo. 61
33481935 2021
46
Structure of trypanosome coat protein VSGsur and function in suramin resistance. 61
33462435 2021
47
Tsetse blood-meal sources, endosymbionts and trypanosome-associations in the Maasai Mara National Reserve, a wildlife-human-livestock interface. 61
33406097 2021
48
Singly and doubly modified analogues of C20-epi-salinomycin: A new group of antiparasitic agents against Trypanosoma brucei. 61
33071053 2021
49
Improved Access to Diagnostics for Rhodesian Sleeping Sickness around a Conservation Area in Malawi Results in Earlier Detection of Cases and Reduced Mortality. 61
32959623 2020
50
Antischistosomal, antionchocercal and antitrypanosomal potentials of some Ghanaian traditional medicines and their constituents. 61
33382717 2020

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to KEGG:

36
# Name Kegg Source Accession
1 African trypanosomiasis hsa05143

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 TF IL6 IL10 HSPA8 HPR HP
2 extracellular space GO:0005615 9.81 TF IL6 IL10 HSPA8 HPR HP
3 extracellular exosome GO:0070062 9.65 TF MDH2 HSPA8 HPR HP H2AC18
4 spherical high-density lipoprotein particle GO:0034366 9.26 HPR APOA1
5 blood microparticle GO:0072562 9.1 TF HSPA8 HPR HP APOL1 APOA1

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.78 NOS2 IL10 HP CXCL13
2 cellular protein metabolic process GO:0044267 9.73 TF IL6 APOL1 APOA1
3 cellular response to lipopolysaccharide GO:0071222 9.62 NOS2 IL6 IL10 CXCL13
4 receptor-mediated endocytosis GO:0006898 9.56 HPR HP APOL1 APOA1
5 positive regulation of cell death GO:0010942 9.54 PRODH HPR HP
6 acute inflammatory response GO:0002526 9.49 HPR HP
7 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.46 IL10 APOA1
8 negative regulation of cytokine production involved in immune response GO:0002719 9.4 IL10 APOA1
9 spermidine biosynthetic process GO:0008295 9.16 SRM AMD1
10 polyamine biosynthetic process GO:0006596 9.13 SRM ODC1 AMD1
11 polyamine metabolic process GO:0006595 8.8 SRM ODC1 AMD1

Molecular functions related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemoglobin binding GO:0030492 8.96 HPR HP
2 NADP binding GO:0050661 8.8 NOS2 GSR GAPDH

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....